Quinolone compounds enhance delta-aminolevulinic acid-induced accumulation of protoporphyrin IX and photosensitivity of tumour cells.
Exogenous δ-aminolevulinic acid (ALA)-induced photodynamic therapy (PDT) has been used in the treatment of cancer. To obtain a high efficacy of ALA-PDT, we have screened various chemicals affecting ALA-induced accumulation of protoporphyrin in cancerous cells. When HeLa cells were treated with quinolone chemicals including enoxacin, ciprofloxacin or norfloxacin, the ALA-induced photodamage accompanied by the accumulation of protoporphyrin was stronger than that with ALA alone. Thus, quinolone compounds such as enoxacin, ciprofloxacin and norfloxacin enhanced ALA-induced photodamage. The increased ALA-induced photodamage in enoxacin-treated HeLa cells was decreased by haemin or ferric-nitrilotriacetate (Fe-NTA), suggesting that an increase in iron supply cancels the accumulation of protoporphyrin. On the other hand, the treatment of the cells with ALA plus an inhibitor of haem oxygenase, Sn-protoporphyrin, led to an increase in the photodamage and the accumulation of protoporphyrin compared with those upon treatment with ALA alone, indicating that the cessation of recycling of iron from haem augments the accumulation. The use of quinolones plus Sn-protoporphyrin strongly enhances ALA-induced photodamage. To examine the mechanisms involved in the increased accumulation of protoporphyrin, we incubated ferric chloride with an equivalent amount of quinolones. Iron-quinolone complexes with visible colours with a maximum at 450 nm were formed. The levels of iron-metabolizing proteins in enoxacin- or ciprofloxacin-treated cells changed, indicating that quinolones decrease iron utilization for haem biosynthesis. Hence, we now propose that the use of quinolones in combination with ALA may be an extremely effective approach for the treatment modalities for PDT of various tumour tissues in clinical practice.
Ohgari
Yoshiko
Y
Department of Biotechnology, Kyoto Institute of Technology, Kyoto, Japan.
Miyata
Yoshinobu
Y
Chau
Tuan Thanh
TT
Kitajima
Sakihito
S
Adachi
Yasushi
Y
Taketani
Shigeru
S
D000622:Aminolevulinic Acid / Q000737:chemistry / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D005290:Ferric Compounds / Q000378:metabolism; D024841:Fluoroquinolones / Q000737:chemistry / Q000494:pharmacology*; D006367:HeLa Cells; D006419:Heme Oxygenase (Decyclizing) / Q000037:antagonists & inhibitors / Q000378:metabolism; D006427:Hemin / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism; D008027:Light; D008665:Metalloporphyrins / Q000494:pharmacology; D009571:Nitrilotriacetic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D010084:Oxidation-Reduction; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000737:chemistry / Q000494:pharmacology*; D011524:Protoporphyrins / Q000378:metabolism* / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism; D012878:Skin Neoplasms / Q000378:metabolism / Q000628:therapy
D005290:Ferric Compounds; D024841:Fluoroquinolones; D008665:Metalloporphyrins; D017319:Photosensitizing Agents; D011524:Protoporphyrins; D017382:Reactive Oxygen Species; C025314:ferric citrate; D006427:Hemin; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX; C032628:tin protoporphyrin IX; D007501:Iron; D006419:Heme Oxygenase (Decyclizing); D009571:Nitrilotriacetic Acid; C020326:ferric nitrilotriacetate